-
Uncategorized2 weeks agoCDD to make Eli Lilly models available in CDD Vault
Collaborative Drug Discovery (CDD) has announced an agreement with Eli Lilly to make Lilly’s AI/ML models available in CDD Vault. The models will come from Lilly TuneLab,...
-
Uncategorized2 weeks agoOpinion: Ebola at the World Cup? Here’s what we should actually worry about
As the FIFA World Cup approaches, speculation on social media and cable news has already begun: Could Ebola spread at the tournament? The short answer is...
-
Uncategorized2 weeks agoSTAT+: Oura brings rings to the cuffless blood pressure party
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your...
-
Uncategorized2 weeks ago
The long wait: biopharma job searches often take at least 6 months, BioSpace finds
The long wait: biopharma job searches often take at least 6 months, BioSpace finds
-
Uncategorized2 weeks ago
GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients
The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus...
-
Uncategorized2 weeks agoSTAT+: Blood pressure tech floods the market after FDA relaxes wearables oversight
In early January, the Food and Drug Administration delivered on the Trump administration’s deregulatory promises by allowing more wellness products to be marketed without the agency’s...
-
Uncategorized2 weeks ago
Kailera walks path paved by Lilly in post-IPO ‘catalyst-rich period’
Kailera Therapeutics is advancing a pipeline of weight loss medicines that mirror that of Eli Lilly’s: an injectable GLP-1/GIP dual agonist like Zepbound, an oral GLP-1...
-
Uncategorized2 weeks ago
AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer
Decnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer.
-
Uncategorized2 weeks ago
FDA extends Beren’s rare disease review after info request, further stretching saga
The FDA has delayed its approval decision on Beren Therapeutics’ rare disease drug candidate, extending the asset’s long path toward the U.S. market.
-
Uncategorized2 weeks agoAn ASCO preview: What to watch for at cancer research’s big meeting
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. STAT is also...
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
